We are live on
!
Find out more
First Manhattan Portfolio holdings
AUM
$36.1B
1-Year Est. Return
11.5%
This Fund
S&P 500
This Quarter
Est. Return
+9.64%
1 Year Est. Return
+11.5%
3 Year Est. Return
+74.65%
5 Year Est. Return
+103.66%
10 Year Est. Return
+354.63%
AUM
$27.3B
AUM Growth
+$1.22B
(+4.7%)
Cap. Flow
-$932M
Cap. Flow
% of AUM
-3.41%
Top 10 Holdings %
Top 10 Hldgs %
60.57%
Holding
1,588
New
70
Increased
176
Reduced
495
Closed
161
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Thermo Fisher Scientific
TMO
|
+$128M |
| 2 |
ATVI
Activision Blizzard
ATVI
|
+$67.4M |
| 3 |
XIFR
XPLR Infrastructure LP
XIFR
|
+$63.8M |
| 4 |
UnitedHealth
UNH
|
+$57.4M |
| 5 |
Danaher
DHR
|
+$24.8M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Berkshire Hathaway Class A
BRK.A
|
+$760M |
| 2 |
Amazon
AMZN
|
+$68.5M |
| 3 |
AbbVie
ABBV
|
+$54.2M |
| 4 |
PPLI
People Inc
PPLI
|
+$36.8M |
| 5 |
PNC Financial Services
PNC
|
+$29.8M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Financials | 44.09% |
| 2 | Technology | 18.28% |
| 3 | Healthcare | 10.34% |
| 4 | Consumer Discretionary | 7.89% |
| 5 | Communication Services | 5.03% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
326
Vanguard Russell 2000 ETF
VTWO
$17.5B
| $1.61M | 0.01% |
21,231
-11,340
| -35% | -$817K |
|
327
Apollo Global Management
APO
$70.4B
| $1.6M | 0.01% |
20,855
-12,447
| -37% | -$832K |
|
328
State Street SPDR Portfolio Developed World ex-US ETF
SPDW
$39.9B
| $1.57M | 0.01% |
48,316
| – | – |
|
329
BayCom
BCML
$349M
| $1.57M | 0.01% |
94,240
+8,260
| +10% | +$136K |
|
|
BNY
330
Bank of New York Mellon
BNY
$108B
| $1.57M | 0.01% |
35,276
-8,684
| -20% | -$373K |
|
331
Pan American Silver
PAAS
$18.8B
| $1.56M | 0.01% |
106,864
-16,000
| -13% | -$264K |
|
332
Vanguard Short-Term Corporate Bond ETF
VCSH
$44.7B
| $1.54M | 0.01% |
20,387
-3,590
| -15% | -$273K |
|
333
Cabaletta Bio
CABA
$439M
| $1.52M | 0.01% |
+117,600
| New | +$1.28M |
|
334
iShares Core S&P 500 ETF
IVV
$880B
| $1.47M | 0.01% |
3,296
-467
| -12% | -$197K |
|
335
Vanguard Ultra-Short Bond ETF
VUSB
$8.93B
| $1.46M | 0.01% |
+29,725
| New | +$1.46M |
|
336
Phillips 66
PSX
$83.2B
| $1.46M | 0.01% |
15,259
-125
| -0.8% | -$12.2K |
|
337
Invesco S&P 500 Equal Weight ETF
RSP
$96.2B
| $1.44M | 0.01% |
13,156
+4,895
| +59% | +$705K |
|
338
Everest Group
EG
$15.2B
| $1.44M | 0.01% |
4,200
| – | – |
|
339
Marathon Petroleum
MPC
$90.7B
| $1.43M | 0.01% |
12,303
-600
| -5% | -$69.8K |
|
340
Vulcan Materials
VMC
$36.3B
| $1.43M | 0.01% |
6,339
-2,400
| -27% | -$460K |
|
|
TRST
341
Trustco Bank Corp NY
TRST
$1.01B
| $1.42M | 0.01% |
49,733
-5,235
| -10% | -$154K |
|
342
Citizens Financial Group
CFG
$30.5B
| $1.42M | 0.01% |
54,396
-23,435
| -30% | -$646K |
|
343
Yum China
YUMC
$14.9B
| $1.4M | 0.01% |
24,811
-10,863
| -30% | -$655K |
|
344
Franklin Electric
FELE
$4.7B
| $1.39M | 0.01% |
13,500
| – | – |
|
345
SentinelOne
S
$6.26B
| $1.37M | 0.01% |
90,951
-31,655
| -26% | -$535K |
|
346
Vornado Realty Trust
VNO
$7.55B
| $1.37M | 0.01% |
75,307
-4,690
| -6% | -$69.1K |
|
347
Northrop Grumman
NOC
$76.4B
| $1.35M | 0.01% |
2,970
+153
| +5% | +$69.4K |
|
|
GOOS
348
Canada Goose Holdings
GOOS
$872M
| $1.34M | ﹤0.01% |
75,414
-150
| -0.2% | -$2.7K |
|
349
Pinnacle West Capital
PNW
$12.8B
| $1.34M | ﹤0.01% |
16,429
-9,275
| -36% | -$740K |
|
350
ProShares Ultra Health Care
RXL
$84.7M
| $1.33M | ﹤0.01% |
29,850
| – | – |
|
Similar funds
SAM
First Manhattan's Q2 2023 Portfolio in Review
As of Q2 2023, First Manhattan held 1,588 positions worth $27.3B, up 4.7% from $26.1B the previous quarter. Its ten largest holdings account for 61% of the portfolio.
First Manhattan withdrew a net $932M in Q2 2023, closing 161 positions and reducing 495 holdings. Its most notable exit was Enanta Pharmaceuticals, an estimated $10.7M position sold in full.
By sector, the portfolio is most concentrated in Financials at 44% of assets, down from 45% a quarter earlier, followed by Technology and Healthcare.
Against the trend, First Manhattan opened a new position in Mersana Therapeutics worth $1.87M.
- First Manhattan's largest Q2 2023 buy was Mersana Therapeutics: 22,784 shares worth $1.87M.
- First Manhattan added most to Thermo Fisher Scientific in Q2 2023, an estimated $128M increase.
- First Manhattan's biggest Q2 2023 reduction was Berkshire Hathaway Class A, cutting an estimated $760M.
- First Manhattan fully exited Enanta Pharmaceuticals in Q2 2023, selling an estimated $10.7M.
- First Manhattan's ten largest holdings make up 61% of its $27.3B portfolio in Q2 2023.
- First Manhattan opened 70 new positions and closed 161 in Q2 2023.
- First Manhattan's portfolio value rose 4.7% quarter-over-quarter to $27.3B.
Based on First Manhattan's 13F filing for Q2 2023, filed 14 Aug 2023.